美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

2倍做多NVO ETF-Defiance

12.46

+0.06000.48%

盤後：12.480.0200+0.16%19:58 EDT

成交量：126.94萬

成交額：1,568.08萬

市值：4,221.57萬

市盈率：- -

高：12.76

開：12.68

低：12.04

收：12.40

52周最高：72.16

52周最低：9.23

股本：338.81萬

流通股本：338.81萬

量比：0.94

換手率：37.47%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

諾和諾德人員調整持續新增招聘2000人

环球市场播报

諾和諾德(NVO)股票4月15日盤中上漲3.55%：投資者必看的核心信息

TradingKey中文

諾和諾德與OpenAI達成戰略合作；再生元牽手Telix

21世纪经济报道

諾和諾德全球高級副總裁兼大中國區總裁蔡琰：立足司美原研優勢挑戰中尋找更大機遇

21世纪经济报道

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVOX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":12.46,"timestamp":1776369600000,"preClose":12.4,"halted":0,"volume":1269429,"hourTrading":{"tag":"盘后","latestPrice":12.48,"preClose":12.46,"latestTime":"19:58 EDT","volume":16102,"amount":200598.3095,"timestamp":1776383910971,"change":0.02,"changeRate":0.001605,"amplitude":0.004013},"delay":0,"changeRate":0.004838709677419395,"floatShares":3388101,"shares":3388101,"eps":0,"marketStatus":"未開盤","change":0.06,"latestTime":"04-16 16:00:00 EDT","open":12.68,"high":12.76,"low":12.04,"amount":15680782.939983,"amplitude":0.058065,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":12.4,"sharesOutstanding":4098101,"nav":12.4,"aum":40648452.4,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":12.66,"preClose":12.4,"latestTime":"09:29 EDT","volume":69611,"amount":875701.646452,"timestamp":1776346161376,"change":0.26,"changeRate":0.020968,"amplitude":0.031452},"postHourTrading":{"tag":"盘后","latestPrice":12.48,"preClose":12.46,"latestTime":"19:58 EDT","volume":16102,"amount":200598.3095,"timestamp":1776383910971,"change":0.02,"changeRate":0.001605,"amplitude":0.004013},"volumeRatio":0.93721,"impliedVol":0.9099,"impliedVolPercentile":0.5783},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":3388101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.93721,"shares":3388101,"dividePrice":0,"high":12.76,"amplitude":0.058065,"preClose":12.4,"low":12.04,"week52Low":9.23,"pbRate":"--","week52High":72.16,"institutionHeld":0,"latestPrice":12.46,"eps":0,"divideRate":0,"volume":1269429,"delay":0,"ttmEps":0,"open":12.68,"prevYearClose":21.89,"prevWeekClose":10.51,"prevMonthClose":10.23,"prevQuarterClose":10.23,"fiveDayClose":10.51,"twentyDayClose":10.14,"sixtyDayClose":30.31},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628324530","title":"諾和諾德人員調整持續 新增招聘2000人","url":"https://stock-news.laohu8.com/highlight/detail?id=2628324530","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628324530?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 03:06","pubTimestamp":1776366360,"startTime":"0","endTime":"0","summary":"诺德诺德在经历了一次相当大规模的人员重组之后，今年正在重新招人，新增约2000名员工。据报道，这些新员工中约有1400人已经入职，其中近400人在丹麦。与此同时，离职仍在发生。诺和诺德的员工自愿离职率为5%，而2025年的总流失率接近18%。在新任首席执行官Mike Doustdar领导的大规模重组中，公司裁减了约7800个职位，约占其员工总数的10%，2025年年底的员工总数约为69505人。此次裁员的影响范围并不局限于基层，也波及了高级管理层，足见变革之深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-17/doc-inhutspq2543883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0154236417.USD","BK4007","LU1093756325.SGD","NVOX","BK4588","NVO","BK4585","BK4532","BK4599","LU1093756168.USD","NVOH","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627286232","title":"諾和諾德(NVO)股票4月15日盤中上漲3.55%：投資者必看的核心信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2627286232","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627286232?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 03:16","pubTimestamp":1776280594,"startTime":"0","endTime":"0","summary":"• 诺和诺德与 OpenAI 达成合作，旨在将人工智能整合到其业务运营的各个环节。\n• AI 旨在加强药物发现、生产制造和商业策略。\n• 此次合作被视为诺和诺德维持制药行业竞争力的催化剂。","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260204/novo-097495ca9dea48fc8abd9bbb031282c3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/261786892-market-movers-nvo-20260415","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","BK4588","NVOH","LU1093756325.SGD","BK4599","BK4585","IE00BZ1G4Q59.USD","LU0154236417.USD","BK7104","NVOX","IE00BKVL7J92.USD","NVO","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"諾和諾德與OpenAI達成戰略合作；再生元牽手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627045478?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVOX","IE00BZ1G4Q59.USD","BK4599","301087","BK4007","LU1093756168.USD","IE00BKVL7J92.USD","688177","600513","600196","LU1093756325.SGD","NVO","002437","BK4532","REGN","LU0154236417.USD","BK4585","300558","NVOH","603087","02196","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420487","title":"諾和諾德全球高級副總裁兼大中國區總裁蔡琰：立足司美原研優勢 挑戰中尋找更大機遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420487","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420487?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 07:00","pubTimestamp":1776207600,"startTime":"0","endTime":"0","summary":"2026年3月，诺和诺德明星产品司美格鲁肽核心化合物在中国的专利到期。随着这一时间节点的到来，国内多款生物类似药的申报已进入冲刺阶段，市场对这家丹麦制药巨头在华策略的关注度持续升温。“专利到期不是终点。”履新刚满一个月的诺和诺德全球高级副总裁兼大中国区总裁蔡琰博士，在其首场媒体交流活动中给出了明确回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705008845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705008845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NVOH","BK4007","NVO","BK4585","LU0154236417.USD","IE00BKVL7J92.USD","BK4532","BK4599","LU1093756325.SGD","NVOX","BK4588","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":50,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}